Medication info
Lyrica Capsule 75 mg (Pregabalin)

Lyrica Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Geonil Biopharm Co., Ltd.
Appearance
Hard capsule with upper reddish-brown and lower white color containing white or light yellow powder
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201903451 · Approved 2019.05.28 · Insurance code 073000620

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of this medicine, as pregabalin, in 2 divided doses orally, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) Peripheral neuropathic pain — Adults: The starting dose of this medicine may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If needed, it may thereafter be increased at 7-day intervals to a maximum of 600 mg per day. Central neuropathic pain — Adults: The starting dose of this medicine may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) Epilepsy — Adults: The starting dose of this medicine may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If needed, it may thereafter be increased at 7-day intervals to a maximum of 600 mg per day. The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr) ≥60 mL/min: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance (CLcr) ≥30 -<60 mL/min: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance (CLcr) ≥15 -<30 mL/min: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance (CLcr) <15 mL/min: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Starting dose 25 mg, maximum dose 100 mg, single dose In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an extra supplemental dose should be administered promptly after every 4 hours of hemodialysis. TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: Supplemental dose refers to an additional dose given as a single dose. No dose adjustment is necessary in patients with hepatic impairment. Elderly patients (65 years of age and older): Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Geonil Biopharm Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to relieve peripheral and central neuropathic pain in adults. It is also effective as an adjunctive treatment for partial seizures in patients with epilepsy, whether accompanied by secondary general symptoms or not. Additionally, it helps in the treatment of fibromyalgia. Thus, it is used to improve various neurological disorders and pain symptoms.

How to take

Adult dose

Administer the total daily dose of this medicine, as pregabalin, in 2 divided doses orally, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) Peripheral neuropathic pain — Adults: The starting dose of this medicine may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If needed, it may thereafter be increased at 7-day intervals to a maximum of 600 mg per day. Central neuropathic pain — Adults: The starting dose of this medicine may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) Epilepsy — Adults: The starting dose of this medicine may be 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If needed, it may thereafter be increased at 7-day intervals to a maximum of 600 mg per day. The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr) ≥60 mL/min: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance (CLcr) ≥30 -<60 mL/min: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance (CLcr) ≥15 -<30 mL/min: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance (CLcr) <15 mL/min: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Starting dose 25 mg, maximum dose 100 mg, single dose In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an extra supplemental dose should be administered promptly after every 4 hours of hemodialysis. TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: Supplemental dose refers to an additional dose given as a single dose. No dose adjustment is necessary in patients with hepatic impairment. Elderly patients (65 years of age and older): Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so patients should be closely monitored for signs of depression, mood changes, or abnormal behavior while taking it. Patients allergic to any component of this medication or those with specific genetic metabolic disorders should not take it. Diabetic patients should be cautious as weight gain may require adjustments to their blood sugar medications. If serious allergic reactions, such as angioedema, occur, the medication should be stopped immediately and healthcare providers should be consulted. Elderly patients are at risk of falls due to dizziness or drowsiness, and therefore should be particularly cautious during the initial dosing. Some patients may experience blurred vision or changes in vision; if this occurs, consult a physician. Discontinuation of the medication may lead to withdrawal symptoms such as insomnia, headache, and anxiety, hence it is advisable to taper off gradually under medical guidance. There is a risk of drug abuse; thus, patients with a history of mental illness or substance abuse should be especially monitored for unusual behavior. Patients with impaired renal function may require dose adjustments. Patients with cardiovascular diseases should also use this medication cautiously. Caution is warranted when taking this medication alongside opioid analgesics as it may enhance central nervous system depressant effects. Patients with respiratory diseases or renal impairment, as well as the elderly, may face a risk of respiratory depression and may require dose adjustments. In early pregnancy, this medication should be avoided due to the risk of fetal malformation and females of childbearing potential should use effective contraception. During breastfeeding, this medication can be passed into breast milk, so careful consideration should be given regarding the continuation of breastfeeding and the necessity of treatment. Be cautious while driving or operating machinery due to the risk of accidents caused by dizziness or drowsiness. This medication can cause severe skin reactions, and if skin rashes or edema occur, it should be discontinued immediately. In cases of overdose, symptoms such as confusion, drowsiness, and depression may occur, and blood dialysis may be necessary if required. Special caution is needed for children and the elderly when taking this medication, and children should be kept out of reach.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • swelling around the mouth
  • upper respiratory edema
  • dizziness
  • drowsiness
Show 191 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • impaired respiratory function
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • increased saliva secretion
  • gastroesophageal reflux
  • decreased oral sensation
  • ascites
  • swallowing difficulty
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falling
  • feeling intoxicated
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • directional perception disorder
  • irritability
  • blessedness
  • decreased libido
  • depersonalization
  • sexual hypersensitivity
  • restlessness
  • mood fluctuation
  • emotional decrease
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • flat affect
  • ataxia
  • abnormal motor coordination
  • equilibrium disorder
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • altered sensation
  • decreased sensation
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorder
  • paroxysmal muscle spasms
  • reduced reflexes
  • abnormal movement
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensations
  • tremors with activity
  • syncope
  • confusion
  • hypokinesia
  • olfactory abnormalities
  • loss of taste
  • writing difficulties
  • diplopia
  • dry eyes
  • eye swelling
  • vision loss
  • ocular pain
  • eye fatigue
  • increased tear secretion
  • ocular irritation
  • mydriasis
  • during vibration
  • changes in depth perception
  • strabismus
  • brightness of vision
  • vertigo
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • homogenous bradycardia
  • homogenous tachycardia
  • homogenous arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • apathy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confusion state
  • agitation
  • restlessness
  • seizures
  • affective disorder
  • drowsiness
  • confusion state
  • depression
  • agitation
  • restlessness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly closed container. It is recommended to keep the storage temperature between 15 and 30 degrees Celsius. Doing so can help preserve the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Hard capsule with upper reddish-brown and lower white color containing white or light yellow powder

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.